Published in Mol Cancer Ther on February 01, 2007
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway. PLoS One (2012) 0.81
Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia (2012) 0.81
Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation system. PLoS One (2013) 0.78
Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model. Transl Oncol (2014) 0.78
Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells. PLoS One (2014) 0.76
Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors. Biomed Res Int (2014) 0.75
Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med (2009) 2.60
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood (2005) 2.39
Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol (2009) 2.11
Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol (2009) 1.76
Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther (2011) 1.70
Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells (2003) 1.70
Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood (2009) 1.70
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy (2011) 1.65
Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood (2005) 1.60
MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci (2003) 1.54
Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. Cytotherapy (2012) 1.53
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy (2013) 1.52
Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res (2008) 1.51
Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol (2007) 1.41
Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg (2003) 1.39
Retroviral delivery of connexin genes to human breast tumor cells inhibits in vivo tumor growth by a mechanism that is independent of significant gap junctional intercellular communication. J Biol Chem (2002) 1.37
A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med (2009) 1.31
Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. J Cell Biochem (2004) 1.29
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood (2008) 1.26
Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther (2009) 1.24
Periostin, a member of a novel family of vitamin K-dependent proteins, is expressed by mesenchymal stromal cells. J Biol Chem (2008) 1.24
Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem (2004) 1.24
Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells (2007) 1.22
The stem cell research environment: a patchwork of patchworks. Stem Cell Rev (2009) 1.21
IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells. J Immunol (2014) 1.19
Large-scale transient transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency. Biotechnol Bioeng (2003) 1.18
Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther (2008) 1.17
Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell (2012) 1.16
Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine. J Immunol (2009) 1.15
LGI1 is a Nogo receptor 1 ligand that antagonizes myelin-based growth inhibition. J Neurosci (2010) 1.14
Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection. Am J Physiol Renal Physiol (2010) 1.13
Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood (2011) 1.10
Down-regulation of the mixed-lineage dual leucine zipper-bearing kinase by heat shock protein 70 and its co-chaperone CHIP. J Biol Chem (2006) 1.09
Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol (2010) 1.08
Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood (2009) 1.06
Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis (2005) 1.06
A novel Schistosoma mansoni G protein-coupled receptor is responsive to histamine. Mol Biochem Parasitol (2002) 1.06
Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis (2005) 1.05
Improving glucose and glutamine metabolism of human HEK 293 and Trichoplusia ni insect cells engineered to express a cytosolic pyruvate carboxylase enzyme. Biotechnol Prog (2003) 1.04
Transient expression and purification of chimeric heavy chain antibodies. Protein Expr Purif (2008) 1.03
Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett (2009) 1.02
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res (2005) 1.02
Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol Bioeng (2007) 1.02
IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood (2011) 1.02
Roles of FGF signaling in stem cell self-renewal, senescence and aging. Aging (Albany NY) (2011) 1.02
The axonal repellent, Slit2, inhibits directional migration of circulating neutrophils. J Leukoc Biol (2009) 1.02
Stem cell research ethics: consensus statement on emerging issues. J Obstet Gynaecol Can (2007) 1.02
Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition. Stem Cells (2009) 1.00
Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol (2006) 0.99
Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther (2004) 0.98
Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs (2013) 0.98
Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnol (2008) 0.97
Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol (2006) 0.97
Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res (2004) 0.97
MSCs: science and trials. Nat Med (2013) 0.97
Purification and characterization of a recombinant G-protein-coupled receptor, Saccharomyces cerevisiae Ste2p, transiently expressed in HEK293 EBNA1 cells. Biochemistry (2005) 0.96
Bone marrow mesenchymal stromal cell therapy for external urethral sphincter restoration in a rat model of stress urinary incontinence. Neurourol Urodyn (2010) 0.96
Purification of recombinant proteins from mammalian cell culture using a generic double-affinity chromatography scheme. Protein Expr Purif (2005) 0.96
In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res (2002) 0.96
GM-CSF-based fusion cytokines as ligands for immune modulation. J Immunol (2011) 0.96
Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res (2008) 0.95
Epidermal growth factor and perlecan fragments produced by apoptotic endothelial cells co-ordinately activate ERK1/2-dependent antiapoptotic pathways in mesenchymal stem cells. Stem Cells (2010) 0.95
CD34 expression on murine marrow-derived mesenchymal stromal cells: impact on neovascularization. Exp Hematol (2007) 0.94
Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Exp Hematol (2003) 0.94
An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J Immunol (2009) 0.93
TGF beta secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. Cancer Immunol Immunother (2008) 0.93
Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. Stem Cells (2009) 0.93
R-spondin 2 signalling mediates susceptibility to fatal infectious diarrhoea. Nat Commun (2013) 0.93
Limiting factors governing protein expression following polyethylenimine-mediated gene transfer in HEK293-EBNA1 cells. J Biotechnol (2006) 0.92
Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII. BMC Biotechnol (2011) 0.92
New insights on translational development of mesenchymal stromal cells for suppressor therapy. J Cell Physiol (2012) 0.92
Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res (2004) 0.92
MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival. J Biol Chem (2007) 0.91
The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials (2013) 0.91
Biotransformation of polybrominated diphenyl ethers and polychlorinated biphenyls in beluga whale (Delphinapterus leucas) and rat mammalian model using an in vitro hepatic microsomal assay. Aquat Toxicol (2005) 0.91
A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood (2006) 0.91
Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton. FASEB J (2007) 0.90
A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther (2010) 0.90
Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther (2008) 0.90
A MCP1 fusokine with CCR2-specific tumoricidal activity. Mol Cancer (2011) 0.90
Transfection of HEK293-EBNA1 Cells in Suspension with Linear PEI for Production of Recombinant Proteins. CSH Protoc (2008) 0.89